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Abstract 
Myeloid cells are recruited to damaged tissues where they can resolve infections and 
tumor growth or stimulate wound healing and tumor progression. Recruitment of these 
cells is regulated by integrins, a family of adhesion receptors that includes integrin 
CD11b. Here we report that, unexpectedly, integrin CD11b does not regulate myeloid 
cell recruitment to tumors but instead controls myeloid cell polarization and tumor 
growth. CD11b activation promotes pro-inflammatory macrophage polarization by 
stimulating expression of microRNA Let7a. In contrast, inhibition of CD11b prevents 
Let7a expression and induces cMyc expression, leading to immune suppressive 
macrophage polarization, vascular maturation and accelerated tumor growth. 
Pharmacological activation of CD11b with a small molecule agonist, Leukadherin 1 
(LA1), promotes pro-inflammatory macrophage polarization and suppresses tumor 
growth in animal models of murine and human cancer. These studies identify CD11b as 
negative regulator of immune suppression and a target for cancer immune therapy. 
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Introduction  
 
 Macrophages, monocytes, neutrophils, and other myeloid cells play important 
roles during acute and chronic inflammation. Pro-inflammatory myeloid cells stimulate 
cytotoxic T cells to suppress infectious disease and tumor growth, while immune 
suppressive myeloid cells promote tumor progression and wound healing1,2,3,4. During 
acute and chronic inflammation, macrophages express pro-inflammatory cytokines, as 
well as reactive nitrogen and oxygen species, that can kill pathogens as well as normal 
cells3. In contrast, in neoplastic and parasitic diseases, macrophages and immature 
monocytes and granulocytes (myeloid-derived suppressor cells) express cytokines that 
induce immune suppression, angiogenesis and cancer progression5,6. Macrophages 
isolated from murine and human tumors exhibit a primarily immunosuppressive 
phenotype7.  
 Although it is well established that tumor-associated macrophages (TAM) are 
abundant within the tumor microenvironment and play essential roles in tumor immune 
suppression and progression1,2,3,4,5,6,7, the molecular mechanisms that regulate these 
tumor-promoting functions of TAMs remain incompletely clear.  However, recent studies 
have shown that signaling pathways regulated by integrins, CSF1R, PI3Kγ and BTK 
control myeloid cell trafficking into tumors as well as macrophage polarization and 
inhibitors of these molecules are in clinical development for cancer 
therapy8,9,10,11,12,13,14,15. 
 Myeloid cells as well as lymphocytes rely on cell adhesion receptors for 
trafficking into inflamed tissues and tumors2,13,14,15. Our previous studies revealed that 
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immune cell adhesion receptors play critical roles during tumor progression. We found 
that the integrin α4β1, a receptor for fibronectin and VCAM-1, is required for myeloid cell 
trafficking into tumors as well as subsequent tumor progression13,14,15. These same 
studies found that the myeloid cell integrin, αMβ2 (CD11b/CD18), a receptor for 
complement, fibrinogen and endothelial cell ICAM-1, is not required for adhesion to 
endothelium or trafficking into tumors15. In contrast, CD11b/CD18 has been shown to 
mediate macrophage adhesion, migration, chemotaxis and accumulation during 
inflammation16,17,18. As integrin CD11b plays important roles during inflammation, we set 
out to identify whether this integrin regulates immune responses during tumor 
progression. 
  We report here that the integrin CD11b/CD18 regulates macrophage polarization 
by promoting miR-Let7a-dependent pro-inflammatory macrophage transcription, thereby 
restraining immunosuppressive macrophage polarization. Using genetic and 
pharmaceutical approaches, we show that CD11b signaling inhibits immune 
suppression, modulates neovascularization and promotes anti-tumor immune 
responses in models of murine and human cancer.  We also show that a small molecule 
CD11b agonist, Leukadherin 1, inhibits anti-inflammatory macrophage polarization to 
suppress tumor growth and enhance survival in animal models of murine and human 
cancer.  
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Results 
 
Integrin CD11b regulates macrophage polarization 
We previously reported that the VCAM receptor integrin α4β1  promotes myeloid cell 
recruitment from the bone marrow to the tumor microenvironment, thereby stimulating 
immune suppression, angiogenesis and tumor progression2,13,14,15. In contrast to its role 
in regulating recruitment of myeloid cells to tissues during acute inflammation16,17,18, we 
found that CD11b (αMβ2), a myeloid cell integrin receptor for ICAM-1 and fibrinogen, 
does not affect myeloid cell recruitment to tumors, as global deletion of CD11b in Itgam-
/- mice has no effect on the number of myeloid cells in circulation or in the number of 
cell recruited to tumors (Supplementary Figure 1; Supplementary Figure 2a-d). 
Surprisingly, however, we found that integrin CD11b plays an essential role in regulating 
macrophage polarization. Itgam-/- macrophages exhibited enhanced immune 
suppressive gene and protein expression and strongly reduced pro-inflammatory gene 
and protein expression compared with WT macrophages, whether stimulated under 
basal, IL-4 or IFNγ/LPS stimulation conditions (Figure 1a, Supplementary Figure 2e-f). 
To determine whether CD11b also regulates macrophage polarization in vivo, we 
isolated and characterized F4/80+ TAMs from LLC tumors grown in Itgam-/- and WT 
mice. We found that Itgam-/- TAMs also expressed significantly higher levels of mRNAs 
associated with immune suppression and angiogenesis, such as Arg1, Tgfb, Il10, Il6 
and Pdgfb, and significantly lower expression of genes associated with immune 
stimulation, such as Ifng, Nos2, and Tnfa than did WT TAMs (Figure 1b, Supplementary 
Figure 2g).  
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Importantly, transient siRNA-mediated knockdown of CD11b in in vitro cultured 
macrophages elevated immune suppressive gene expression and decreased immune 
stimulatory gene expression, effect that are comparable to CD11b deletion (Figure 1c), 
indicating that even transient loss of CD11b controls macrophage immune suppressive 
gene expression. To address whether CD11b expression or function controls 
macrophage gene expression, we examined the effect of inhibitory CD11b antibodies 
on macrophage mRNA expression. Blockade of murine macrophage CD11b mediated 
attachment to ICAM-1-coated substrates by anti-CD11b neutralizing antibodies also 
induced immune suppressive mRNA expression in macrophages (Figure 1d). Similarly, 
adhesion of macrophages to the integrin α4β1 substrate VCAM-1 or loss of attachment 
by suspension culture promoted murine and human immune suppressive transcription, 
while attachment to ICAM-1 coated surfaces promoted immune stimulatory transcription 
(Figure 1e-f, Supplementary Figure 1h), indicating that ligation of CD11b controls 
immune stimulatory macrophage transcription.  
 
The loss of pro-inflammatory cytokine expression in Itgam-/- macrophages suggested 
that CD11b may regulate activation of pro-inflammatory transcription factors, such as 
NFκB. We found that Itgam-/- macrophages exhibited reduced NFκB serine 536 
phosphorylation (an indication of reduced activation19) in response to LPS stimulation 
compared to WT macrophages, suggesting CD11b plays a role in NFκB activation 
(Figure 1g). As other studies have implicated CD11b in the promotion of pro-
inflammatory responses of monocytes and dendritic cells through direct interactions of 
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LPS with integrin beta2 extracellular domains20,21, our results indicate that CD11b 
activation and signaling play key roles in the regulation of macrophage polarization in 
vitro and in vivo. 
 
Macrophage CD11b regulates tumor growth 
Our data indicate that Itgam-/- bone marrow derived and tumor associated 
macrophages exhibit more immune suppressive transcriptional profiles than WT 
macrophages. To determine if this difference affects tumor growth, we adoptively 
transferred WT or Itgam-/- bone marrow derived or tumor associated macrophages with 
tumor cells into recipient WT or Itgam-/- mice. Previously, we demonstrated that 
adoptively transferred, immune suppressive BMDM or TAMs can stimulate tumor 
growth9,10. Remarkably, bone marrow-derived Itgam-/- macrophages (Figure 1h) as well 
as tumor-derived Itgam-/- macrophages (Figure 1i) potently stimulated tumor growth 
compared with WT macrophages in both WT and Itgam-/- mice. As Itgam-/- 
macrophages exhibit an immune suppressive transcriptional profile (Figure 1b), and 
tumors derived from Itgam-/- mice exhibit an overall immune suppressive transcriptional 
profile (Figure 1j), these data suggested that CD11b expression or activation might 
impact overall tumor growth. Indeed, we found that subcutaneous (LLC), orthotopic 
(melanoma) and autochthonous (PyMT) tumors grew more aggressively in Itgam-/- than 
in WT mice (Figure 1k). As Itgam-/- mice exhibited substantially more CD4+Foxp3+ Tregs 
and fewer CD8+ T cells in tumors than WT mice (Supplementary Figure 3a-b), our 
studies support the conclusion that CD11b plays a key role in regulating the overall 
immune response in tumors.  
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Prior studies have shown that Isoleucine 332 in the CD11b molecule serves as an 
allosteric switch controlling the adhesion receptor's activation and shape22. To 
determine whether CD11b activation controls tumor development, we generated a 
constitutively activated CD11b knockin mouse strain (C57BL/6 ITGAMI332G by 
introducing an I332G point mutation in the murine Itgam gene. I332G knockin mice 
express normal levels of cell surface CD11b on both monocytes and granulocytes and 
exhibit normal levels of all blood cell level (Supplementary Figure 3c-d). In vitro 
adhesion assays with bone marrow derived macrophages from these mice showed that 
I332G cells express constitutively active CD11b (Supplementary Figure 3e). 
Importantly, I332G Itgam knockin mice exhibited significantly reduced LLC tumor growth 
(Figure 1k). Thus, while CD11b deletion stimulates anti-inflammatory macrophage 
polarization, inhibits CD8+ T cell recruitment and promotes tumor growth, CD11b 
activation potently inhibits tumor growth. These studies indicate that macrophage 
CD11b plays a critical functional role in controlling tumor growth.  
 
Immune suppressive signals inhibit CD11b expression 
To determine whether signals associated with the tumor microenvironment can alter 
CD11b expression and subsequently affect myeloid cell polarization, we evaluated the 
effect of macrophage media (mCSF-, IL-4- and IFNγ/LPS) on cell surface CD11b 
expression in bone marrow derived macrophages. While the immune suppressive 
cytokine IL-4 reduced CD11b expression, the pro-inflammatory stimuli IFNγ/LPS 
enhanced CD11b surface expression compared to levels expressed on mCSF-
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stimulated macrophages (Supplementary Figure 4a-b). Additionally, the immune 
suppressive factor TGFβ, but not IL-10, inhibited CD11b surface expression 
(Supplementary Figure 4c); TGFβ, IL-4 and tumor cell conditioned medium (TCM) each 
also suppressed Cd11b mRNA expression (Supplementary Figure 4d). Importantly, 
TGFβ and TCM reduced CD11b cell surface expression and stimulated immune 
suppressive transcription while inhibiting immune stimulatory transcription in a manner 
that was reversed by the TGFβR1 inhibitor SB525334 (Supplementary Figure 4e-g). 
These data indicate that cytokines such as TGFβ in the tumor microenvironment 
suppress CD11b expression or activation, thereby promoting immune suppressive 
macrophage polarization.  
 
Macrophage CD11b regulates blood vessel stability 
Macrophages not only control immune responses but also angiogenesis and 
desmoplasia, by expressing cytokines such as VEGF-A and PDGF-BB, growth factors 
that regulate endothelial cell and vascular smooth muscles/pericytes during 
angiogenesis, respectively2. Tumor blood vessels often consist of a single endothelial 
layer that lacks supporting pericytes or smooth muscle cells; these blood vessels are 
more numerous in tumors than in normal tissues but are aberrantly formed and poorly 
perfuse. In contrast, in tumors with high PDGF to VEGF ratios, blood vessels are lined 
by pericytes, mesenchymal cells that stabilize vessels and promote better tumor 
perfusion23,24,25,26,27. These tumors grow more rapidly than tumors with lower PDGF to 
VEGF ratios but also respond better to chemotherapy and immune therapy due to better 
tumor perfusion24,25,26,27,28,29,30,31,32,33,34,35,36. As Itgam-/- macrophages exhibited high 
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PDGF and low VEGF gene expression (Figure 1a-b), we examined the patterns of 
blood vessel development in Itgam-/- and WT tumors. An assessment of vascular 
patterning in LLC and PyMT tumors from WT and Itgam-/- mice showed that Itgam-/- 
tumors exhibited fewer, longer blood vessels with wider lumens and fewer branch 
points/field than WT tumors (Figure 2a-b; Supplementary Figure 5a). Itgam-/- tumors 
had more blood vessels that were lined with Desmin+, NG2+ or SMA+ pericytes/smooth 
muscle cells than did WT tumors (Figure 2a,c; Supplementary Figure 5b). Accordingly, 
these vessels were less permeable in Itgam-/- mice than in WT mice, as less 
intravascular FITC-dextran leaked into the tumor parenchyma (Figure 2a, 2d). These 
data indicate that the integrin CD11b plays a role in controlling blood vessel maturation. 
We found that gene expression of PDGF-BB but not VEGF-A was strongly enhanced in 
tumors (Figure 2e; Supplementary Figure 5c). Importantly, PDGF-BB protein expression 
was also elevated in Itgam-/- tumors and tumor-derived macrophages compared to WT 
tumors (Figure 2f). Together, these data suggest that macrophage CD11b controls 
tumor vascularization through the constitutive expression of elevated levels of PDGF.  
 
In support of these observations on CD11b roles in neovascularization, we found that 
Itgam-/- mice exhibited a well-developed retinal vascular plexus (Figure 2g, Isolectin B+, 
green) at birth (P1) compared with WT mice, which exhibit undeveloped retinal 
vasculature that expands progressively from postnatal day 1 (P1) to P9. The superficial 
vascular plexus was more developed in Itgam-/- mice from postnatal day P1 through 
postnatal day P9 than in WT neonates (Figure 2g). These results indicate that 
macrophages and CD11b play key roles in the control normal vascular patterning.  
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To investigate whether elevated PDGF-BB is responsible for the enhanced vascular 
maturation and tumor growth in Itgam-/- mice, we treated WT and Itgam-/- mice bearing 
LLC tumors with imatinib, an inhibitor of the PDGF-BB receptor PDGFR1. Imatinib 
treatment suppressed the enhanced tumor growth observed in Itgam-/- mice (Figure 2h-
i). It also increased vascular density and suppressed vascular normalization in Itgam-/- 
mice (Figure 2h-i). Together these results support the concept that integrin CD11b 
modulates vascular development through control of PDGF-BB expression.   
 
CD11b regulates Let7a and c-Myc expression 
CD11b may control anti-inflammatory macrophage polarization through the activation of 
transcription factors such as Stat3, which can promote expression of immune 
suppressive and pro-angiogenic factors such as Arginase 1, Myc and VEGF37,38,39. 
Itgam-/- macrophages exhibit constitutively phosphorylated Stat3 (Figure 3a inset); the 
high levels of immune suppressive factor expression in Itgam-/- macrophages were 
reduced to WT macrophage levels by treatment with the Stat3 inhibitor 5,15-DPP 
(Figure 3a). Surprisingly, however, Stat3 inhibition did not affect the high levels of Il6 
expression observed in Itgam-/- macrophages (Figure 3a). Importantly, IL-6 can directly 
activate Stat338. We found that IL-6 promoted the same pattern of immune suppressive 
polarization in murine and human myeloid cells and macrophages we observed in 
Itgam-/- macrophages (Figure 3b). Together, these results suggested that autocrine IL6 
may drives the constitutively immune suppressive polarization observed in Itgam-/- 
macrophages. In support of this concept, Il6 knockdown decreased expression of 
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constitutive Pdgfb expression in Itgam-/- macrophages (Figure 3c). As TAMs are a 
major source of Il6 expression in tumors15, these results suggest that CD11b serves as 
a natural brake on immune suppression in part through control of myeloid cell 
transcription of Il6.  
 
The Let7 family of microRNAs can controls Il6 expression in tumor and inflammatory 
cells40,41. microRNAs are non-coding RNAs that modulate gene expression at the 
posttranscriptional level by interfering with RNA translation or stability and can 
dramatically impact tumor immune suppression and angiogenesis.42,43 We found that 
miRNA Let7a expression inversely correlated with Il6 expression in murine and human 
macrophages (Supplementary Figure 6a-b). Therefore, we asked whether loss of 
CD11b expression in macrophages affects Let7a expression. Let7a expression was 
ablated in Itgam-/- and Itgam siRNA transduced macrophages and in in the presence of 
neutralizing CD11b antibodies (Figure 3d; Supplementary Figure 6c) in a manner that 
was independent of Lin28, an RNA binding protein that cleaves and inactivates Let7, as 
Lin28 levels were not affected by CD11b expression or activation (Supplementary 
Figure 6b, d-e). CD11b ligation by ICAM-1 promoted time-dependent Let7a expression, 
while inhibiting Il6 expression; conversely, suppression of adhesion inhibited Let7a 
expression and promoted Il6 expression in both murine and human macrophages 
(Figure 3e-f). Importantly, ectopic expression of Let7a miRNA (pre-miRNA) inhibited 
immune suppressive gene expression and stimulated pro-inflammatory gene expression 
in Itgam-/- macrophages, while anti-miRNA Let7a stimulated immune suppressive gene 
expression and inhibited immune stimulatory gene expression in WT macrophages 
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(Figure 3g). Similar to CD11b ablation (Figure 1a), anti-miRNA Let7a stimulated Pdgfb 
expression but had no effect on Vegfa expression (Figure 3h). Together, these results 
indicate that CD11b activation promotes miRNA Let7a expression, which in turn inhibits 
IL6-mediated immune suppressive macrophage gene expression.  
 
c-Myc, a transcription factor that regulates immune suppressive macrophage 
polarization, binds to the Let7 promoter and suppresses its transcription; interestingly 
Let7 can also suppress c-Myc expression44,45. We found that c-Myc gene was 
upregulated in Itgam-/- macrophages compared with WT macrophages (Figure 3i) c-
Myc protein expression and serine 62 phosphorylation, which stabilizes the transcription 
factor46, were also upregulated in Itgam-/- macrophages compared with WT 
macrophages (Figure 3j). We then asked whether inhibition of cMyc function could 
promote Let7 expression and thereby alter macrophage polarization. Importantly, Let7a, 
Let7d and Let7f expression was reduced in Itgam-/- macrophages; however, 
pharmacological inhibition of c-Myc restored Let7 expression in Itgam-/- macrophages 
and reversed the increased immune suppressive gene expression exhibited by Itgam-/- 
macrophages (Figure 3k-l). Together, these data indicate that integrin CD11b functions 
to suppress Myc expression and immune suppressive macrophage polarization in a 
Let7 dependent manner.  
 
Because Let7a inhibits macrophage-mediated Pdgfb expression, we investigated the 
effect of Let7a expression on neovascularization in vitro and in vivo. Endothelial cells 
and vascular smooth muscle cells attached to microcarrier beads were cultured in fibrin 
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gels that contained either WT or Itgam-/- macrophages that were transduced with 
control miRNA, pre-miRNA Let7a, anti-miRNA Let7a or Pdgf-bb siRNA. Itgam-/- 
macrophages stimulated sprout elongation that was inhibited by transduction of 
macrophages with Let7a miRNA or Pdgfb siRNA (Figure 4a-b; Supplementary Figure 
6f). In contrast, expression of anti-miRNA Let7a in WT but not Itgam-/- macrophages 
stimulated sprout elongation (Figure 4a-b; Supplementary Figure 6f). Additionally, 
macrophages transduced with anti-miR Let7a stimulated the formation of mature, 
pericyte-coated blood vessels in bFGF-saturated Matrigel in vivo (Figure 4c). Together, 
these studies show that CD11b controls neovascularization through the regulation of 
Let7a and subsequent PDGF-BB expression. 
 
Myeloid cell Let7a regulates tumor progression 
To test the role of Let7a in the regulation of tumor immune suppression and 
neovascularization, we delivered anti-miR Let7a to tumors in myeloid cell targeted 
nanoparticles in vivo (Figure 4d). We found that integrin αvβ3-targeted nanoparticles 
were specifically taken up by circulating myeloid cells in normal and tumor bearing 
animals (Supplementary Figure 7a-h). Delivery of anti-miRNA Let7a stimulated LLC 
tumor growth, comparable to that observed in Itgam-/- mice (Figure 4d). Although Let7a 
is expressed in immune and non-immune cells in tumors, we found that delivery of anti-
miR Let7a only inhibited Let7a expression in circulating monocytes and in tumor 
associated macrophages but not in other tumor associated cells (Figure 4e). 
Importantly, anti-miRNA Let7a stimulated immune suppressive and pro-angiogenic 
gene expression and inhibited pro-inflammatory gene expression in tumors compared 
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with controls (Figure 4f, Supplementary Figure 8a). Anti-miRNA Let7a also stimulated 
blood vessel normalization in transfected tumors, as vessels were longer, less 
branched, heavily coated with pericytes and less leaky than vessel from control 
transfected tumors (Figure 4g-h). Importantly, anti-Let7a also suppressed CD8+ T cell 
recruitment to tumors and enhanced CD4+ T cell recruitment to tumors (Figure 4i). 
Together, these results indicate that CD11b restrains immune suppression and vascular 
maturation through its regulation of miRNA Let7a. Prior studies have shown that 
increased vascular normalization in tumors can improve tumor perfusion and promote 
responsiveness to therapy23-36. To determine whether the vascular normalization 
induced by anti-miRNA Let7a might enhance the efficacy of chemotherapy by 
increasing tumor perfusion, we treated mice bearing LLC tumors with targeted delivery 
of anti-miRNA Let7a or control miRNA in combination with chemotherapy (gemcitabine) 
(Figure 4j). Whereas anti-miRNA Let7a promoted LLC tumor growth, anti-miRNA Let7a 
combined with gemcitabine substantially reduced tumor growth, consistent with the 
notion that Let7a inhibition increases accessibility of the tumor to chemotherapy (Figure 
4k). In accordance with these results, we found that gemcitabine treatment of Itgam-/- 
mice suppressed tumor growth more profoundly than gemcitabine treatment of WT mice 
(Supplementary Figure 8b). As Itgam-/- exhibited greater perfusion (less vascular leak) 
than WT mice (Supplementary Figure 8c), these studies indicate that CD11b, through 
its effects on miRNA Let7a, plays a critical role in regulating tumor immune and vascular 
responses.  
 
The CD11b agonist LA1 inhibits tumor growth 
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Our results suggested that targeted pharmacologic activation of CD11b in vivo might 
repolarize tumor associated macrophages, with subsequent inhibition of tumor immune 
suppression and tumor growth. We thus investigated the effects of a small molecule 
agonist of CD11b, leukadherin 1 (LA1)47 (Figure 5a) on macrophage polarization and 
tumor growth. LA1 stimulated myeloid cell adhesion to ICAM-1 coated substrates in a 
manner that was inhibited by anti-CD11b-neutralizing antibodies (Figure 5b). LA1 
stimulated macrophage immune response gene expression, illustrated by increases in 
expression of Il1b, Tnfa, Il12, Nos2 and Ifng mRNAs (Supplementary Figure 9a). As 
LA1 stimulated Let7a expression and inhibited Pdgfb and Il6 expression (Figure 5c), 
these results suggested that LA1 might stimulate pro-inflammatory immune responses 
that could inhibit tumor growth in vivo. To assess the effects of LA1 on tumor associated 
macrophages in vivo, tumor associated macrophages were isolated10, treated with LA1 
prior and co-implanted with LLC tumor cells. LA1-treated macrophages completely 
inhibited tumor growth (Figure 5d-e) even though LA1 had no direct effect on LLC or 
macrophage viability (Figure 5e-f). Although LA1 had no effect on CL66-Luc breast 
tumor cell growth in vitro (Supplementary Figure 9b), LA1 potently reduced tumor 
growth in syngeneic, orthotopically implanted CL66-Luc breast tumors more effectively 
than taxol (Figure 5g). LA1 also synergized with irradiation to suppress CL66-Luc breast 
tumor growth (Figure 5h) and suppressed the growth of orthotopic, human MDA-MB-
231 mammary xenograft tumors (Figure 5i). Importantly, LA1 inhibited murine LLC lung 
tumor growth in WT but not in Itgam-/- mice, indicating that LA1 acts through integrin 
CD11b to suppress the growth of tumors (Figure 5j-k).  
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As LA1 treatment increased the presence of MHC-II+ macrophages, typically 
considered immune competent, and decreased the presence of CD206+ macrophages, 
typically considered immune suppressive, in LLC and CL66-Luc tumors (Supplementary 
Figure 9c-d), our studies suggest that LA1 repolarizes tumor associated macrophages. 
Accordingly, we found that LA1 inhibited expression of S100A8 and MMP9 in CD11b+ 
cells in LLC tumors and also inhibited expression of Arginase1, S100A8 and MMP9 in 
CL66-Luc tumors (Supplementary Figure 9e-f). As these proteins are markers of pro-
tumoral macrophages, together these studies indicate that LA1 likely inhibits tumor 
growth by repolarizing tumor associated macrophages. Indeed, LA1 treatment 
increased the presence of CD8+T cells in both LLC and CL66-Luc tumors 
(Supplementary Figure 10a-c). We also observed that LA1 treatment altered 
neovascularization in tumors by decreasing the numbers of SMA+ blood vessels (Figure 
5l). By enhanced the pro-inflammatory immune profile of tumors and inhibiting vascular 
normalization in tumors, the small molecule CD11b agonist LA1 significantly altered 
macrophage polarization, increased CD8+ T cell recruitment to tumors and inhibited 
tumor progression in mouse models of murine and human cancer.  
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Discussion 
 
We identified macrophage integrin CD11b as a critical regulator of pro-inflammatory 
immune responses that prevent cancer progression. Our studies demonstrate that 
CD11b ligation/activation inhibits the immune suppressive transcriptional signature of 
tumor-derived macrophages, stimulates accumulation of CD8+ T cells in tumors and 
suppresses tumor growth. Loss of CD11b expression or function promotes immune 
suppressive gene expression in macrophages in vitro and TAMs in vivo, increases 
FoxP3+CD4+ T cells and decreases CD8+ T cell recruitment to tumors and increases 
tumor growth. In contrast, activation of CD11b with the small molecule agonist LA1 
stimulates macrophage pro-inflammatory transcription and anti-tumor immunity to inhibit 
tumor progression in animal models of cancer.  
 
Using Itgam-/- mice, as well as knockdown and neutralizing antibody approaches, we 
have demonstrated that integrin CD11b is not required for myeloid cell trafficking during 
tumor growth, although other studies have shown CD11b regulates myeloid cell 
recruitment under conditions of acute inflammation.17,18 These differences may arise 
from the unique microenvironment cues and alterations in blood vessel biology 
observed in tumors versus inflamed tissue. Recent studies have shown that signaling 
pathways regulated by TLRs, CSF1R, PI3Kγ and BTK control macrophage 
polarization8,9,10,11,12,13,14,15; here, we showed that CD11b promotes miRNA Let7a 
expression and inhibits Myc expression to control of macrophage polarization and tumor 
immune responses (Schematic, Figure 5m). Taken together, these studies demonstrate 
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that agonists of macrophage integrin CD11b could provide benefit in the treatment of 
cancer.    
 
We observed improved vascular perfusion in CD11b-/- animals. Compared to non-
pathological tissue, tumors display disorganized, and immature blood vessel structures. 
Tumor blood vessels often consist only of a single fenestrated endothelial layer and lack 
the additional coverage of mesenchymal cells, such as pericytes and smooth muscle 
cells, which provide blood vessels with a stable and more mature structure that 
promotes tumor perfusion and better access to 
chemotherapy23,24,25,26,27,28,29,30,31,32,33,34,35,36. In our studies, tumor blood vessels from 
CD11b-/- mice displayed increased pericyte coverage and increased vascular flow 
compared to WT. Indeed, deletion of CD11b or Let7a suppression increases the PDGF-
BB/VEGF-A ratio, resulting in tumors with normalized vessels that stimulate tumor 
growth but are susceptible to cancer chemotherapy.   
 
Integrin CD11b-/- macrophages expressed increased levels of IL-6 that induced the 
expression of STAT3-dependent immunosuppressive cytokines. Decreased integrin 
CD11b expression or activation negatively regulated the expression of miRNA Let-7a in 
macrophages, thereby upregulating intracellular Il6 levels in macrophages. Reduced 
Let-7a expression is associated with malignant transformation of cancer cells and poor 
prognosis in cancer40,41. We found that loss of CD11b down-regulates Let7a, leading to 
elevated Il6 levels and increased activation of STAT3, which were critical for the 
expression of M2-related cytokines. In contrast, recent studies showed that miRNA Let 
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7d-5p and DICER promote the M2 phenotype42. Together, these studies demonstrate 
the critical roles that miRNA species play in the polarization of macrophages and cancer 
growth. 
 
Our studies show loss of Let7 expression in CD11b-/- macrophages induces Myc 
expression; Myc then drives immune suppressive transcription and inhibition of immune 
stimulatory transcription. Although both Myc and NFκB are transiently activated in WT 
IFNγ/LPS stimulated macrophages, NFκB activation is inhibited and Myc is activated in 
IFNγ/LPS stimulated Itgam-/- macrophages, leading to blockade of immune stimulatory 
transcription. These results suggest that Myc may inactivate NFκB in macrophages, 
thereby contributing to immune suppression and enhanced tumor growth 
 
We found that LA1, a potent activator of integrin CD11b/CD18 in vitro and in vivo42, 
could significantly alter macrophage polarization, increase CD8+ T cell recruitment to 
tumors, inhibit tumor progression and prolong survival in mouse models of cancer. To 
determine the role of macrophage CD11b activation in tumor growth, we performed 
adoptive transfer of LA1 treated macrophages; LA1 treated macrophages directly and 
robustly inhibited tumor growth. LA1 effects were lost in Itgam-/- mice, indicating that 
the effects of LA1 on tumor growth depend on intact CD11b. These results indicate that 
LA1 acts on myeloid cells to effect changes in macrophage polarization, vasculogenesis 
and T cell recruitment. As LA1 has also been shown to inhibit bone marrow derived cell 
trafficking to tissues by promoting stable adhesion to endothelium. It is possible that 
LA1 may inhibit immune suppressive myeloid cell trafficking to tumors49. By slowing 
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tumor progression, LA1 may also be useful to suppress the spread of cancer through 
metastasis.  
 
We show that LA1 stimulates a pro-inflammatory phenotype in macrophages in vitro 
and in vitro. To address the direct impact of LA1 treated TAMs on tumor growth, we 
performed adoptive transfer of LA1 treated TAMs with tumor cells. We found that LA1 
treatment of TAMs robustly and rapidly abolished tumor growth. In this model, we 
previously showed that adoptive transfer of immune suppressive macrophages (IL-4 
stimulated) or TAMs promotes tumor growth, while adoptive transfer of immune 
stimulatory macrophages (IFNγ/LPS stimulated) and repolarized TAMs) recruited CD8+ 
T cells to tumors and rapidly abolished tumor growth10. We further showed that showed 
this tumor suppression by adoptively transferred macrophages required IL-12, a pro-
inflammatory factor that recruits and stimulates CD8+ T cell proliferation10.  Thus, we 
conclude by this evidence that LA1 repolarizes TAMs, leading to recruitment and 
activation of CD8+ T cells. As systemic delivery of LA1 also recruits CD8+ T cells and 
repolarizes TAMs in tumor models, these studies indicate that CD11b agonism by LA1 
repolarizes macrophages and stimulates an adaptive immune response.  
 
We tested the role of T cell depletion in the response to LA1 treatment by implanting 
MDA-MB-231 breast tumor cells in SCID mice, which lack T cells. By comparison, we 
implanted CL66 Luc breast tumor cells in syngeneic, immune competent mice. 
Interestingly, LA1 inhibited MDA-MB-231 tumor growth to 50% of that of control treated 
animals. In contrast, LA1 inhibited CL66 Luc tumor growth to 25% of that of control 
tumors. LA1 also repolarized macrophages by stimulating MHCII expression and 
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reducing CD206, Arg1, MMP9 and S100A8 expression in TAMs and promoted CD8+ T 
cell recruitment in this model. Together, these results indicate that LA1 acts on myeloid 
cells to changes tumor associated macrophage polarization leading to increased T cell 
recruitment, and T cell dependent tumor suppression. 
 
However, the partial effect of LA1 on MDA-MB-231 tumors indicates that LA1 (and 
hence CD11b) also affects T cell independent processes to suppress tumor growth.  We 
showed that LA1 reduced inhibiting vascular normalization (as detected by pericyte 
coated blood vessel density) in all tumor models. Our studies indicate that CD11b 
controls innate immune cell polarization and that these cells regulate vascular as well as 
adaptive immune responses in the tumor microenvironment. Together, these results 
indicate that CD11 activation controls tumor macrophage polarization, vasculogenesis 
and T cell recruitment.  
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Methods 
 
Materials: All materials used in this manuscript are publicly available 
 
Regulatory approvals 
 
All animal experiments were performed with approval from the Institutional Animal Care 
and Use Committees of the University of California, San Diego, La Jolla, CA, Rush 
University Medical Center and the University of Miami Leonard M. Miller School of 
Medicine. All use of human peripheral blood leukocytes isolated from outdated 
leukophoresis samples from the San Diego Blood Bank to make macrophages and use 
of human tumor cell lines were conducted with approval (NIH exempt category) from the 
Institutional Review Boards of the University of California, San Diego, La Jolla, CA, and 
Rush University Medical Center. 
 
 
 
Cell lines 
C57BL/6 LLC, B16 melanoma, CL66 breast and MDA-MB-231 breast tumor cells were 
obtained from the American Type Culture Collection (ATCC). Cells were cultured in 
antibiotic- and fungizide-free DMEM or RPMI media containing 10% serum and tested 
negative for mycoplasma using the Mycoplasma Plus PCR primer set from Stratagene 
(La Jolla, CA). All cell lines were authenticated by tumor cell and tumor histology and by 
RNA or DNA sequencing. 
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Mice 
C57BL/6 and CD11b deficient (Itgam-/-) mice in the C57BL/6 background were from 
Jackson Laboratories. For the spontaneous breast cancer model, male PyMT+ mice on 
a C57BL/6 background were crossed with wild type (WT) or Itgam-/- C57BL/6 at the 
University of California, San Diego to generate WT and Itgam-/- P+ females. Wild type 
and CD11b-/- female mice heterozygous for the PyMT transgene were compared to 
each other. All PyMT+ females exhibit adenomas/ early carcinomas by 16 weeks of age 
and late carcinomas by 25 weeks of age.  
 
Generation of the ITGAM I332G knock-in mouse was accomplished by replacing exon 9 
of the ITGAM gene using a targeting construct in which the Ile332 codon was 
substituted with Gly using a site-directed mutagenesis kit. The mutation led to the loss 
of the Exon-9 Bgl II restriction site.  C57BL/6 ES cells with the heterozygous ITGAM 
I332G mutant allele were generated. G418-resistant clones were characterized by PCR, 
sequencing and southern blot analysis. The heterozygous mutant mice were generated 
using the blastocyst injection method. Mice heterozygous for the ITGAM I332G mutation 
were normal, fertile and phenotypically indistinguishable from wild-type (WT) littermates. 
The heterozygous mice were bred with ROSA26::FLPe knockin (JAX Stock No: 
003946) mice to remove the selection cassette. The N2 offspring were backcrossed 
with C57BL/6N for six generations. The C57BL/6N N6 mice were crossed to obtain mice 
homozygous for the ITGAM I332G mutation that were also indistinguishable from wild-
type (WT) littermates. Female nude and Balb/cJ mice at 6 to 8 weeks of age were from 
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Jackson Laboratories and housed under pathogen-free conditions in the animal facility 
at Rush University Medical Center.   
 
Tumor studies 
 
Subcutaneous tumor studies: 5X105 LLC or B16 cells were injected subcutaneously into 
syngeneic (C57BL/6) 6- to 8- week old WT or Itgam-/- mice (n=18). Tumors were 
excised at 7, 14 or 21 days, cryopreserved in OCT, lysed for RNA purification or 
collagenase-digested for flow cytometric analysis of CD11b+, F4/80+ and Gr1+ 
expression. Tumor volumes were calculated using the equation v = (l2 x w)/2. CL66-luc 
cells (0.5 x 106 cells) were suspended in 50 μL of basement membrane extract Matrigel 
(BD Pharmingen) in PBS (1:1) and inoculated orthotopically in the fourth mammary fat 
pad of female Balb/cJ mice. Tumor dimensions were measured every 2 days, and tumor 
volume was calculated using the equation: v = π/6 (length)*(width), where length is the 
longest diameter of the tumor and width is the shorter diameter. Mice were divided into 
four cohorts: vehicle control treated, LA1 only treated, Taxol only treated, LA1 and Taxol 
treated. LA1 (2 mg/kg) was dissolved in 2% DMSO and 1% Tween-20 in saline and 
Taxol (2.5 mg/kg) was dissolved in a 1:1:6 ratio of Cremophor EL: Ethanol: Saline. LA1 
was administered by intraperitoneal injection (i.p) daily, while Taxol was administered 
every other day by i.p injection until end-point. LA1 + Taxol treated mice received LA1 
i.p in the morning followed by Taxol i.p within 4 hours. Tumor burden was evaluated 
every other day by caliper measurements. Prior to tissue collection, mice were 
anesthetized by ketamine/xylazine and the lungs were perfused with PBS followed by 
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10% formalin and harvested for fixation. Mammary tumor tissue was harvested and 
divided for fixation (10% formalin or OCT), snap frozen, or made into single-cell 
suspensions and analyzed by flow cytometric analysis. For survival studies, Balb/c mice 
bearing CL66-derived tumors were treated for 6 weeks after the first treatment and 
monitored thereafter. End point was considered when the tumor reached 2 mm in 
diameter (n=10-15). Alternatively, 5 million MDA-MB 231 human breast cancer cells 
were injected orthotopically in the 4th mammary fat pad of 6-week old female nude mice. 
The tumors were allowed to establish for 35 days (at least 0.5 cm in diameter) and the 
tumor bearing mice were divided into three treatment groups including, vehicle, LA1 
only (i.p; 2.0 mg/kg; daily) and Taxol only (i.p; 2.5 mg/kg every other day). Treatment 
was initiated on day 35 and continued until the end-point at day 58 post-tumor when all 
the mice were sacrifice and tumor tissue was harvested for histological analysis. 
Palpable tumors were measured using digital calipers 3 times weekly during the entire 
experiment to develop tumor growth curves. LA1 treatment of LLC: 7.5X105 LLC cells 
were injected subcutaneously (s.c) into the right flank of syngeneic 6- to 8- week old WT 
or CD11b-/- mice. At 5-8 days post tumor inoculation, tumor-bearing mice were divided 
into the following treatment groups: Vehicle (6% DMSO, 1% Tween-20 in saline), LA1 (6 
mg/kg dissolved in vehicle). Vehicle and LA1 was administered by intraperitoneal 
injection (i.p) daily. Tumor burden was evaluated 2-3 times a week by caliper 
measurements and tumor volumes were calculated using the equation (l2 x w)/2. 
Tumors were harvested at 3 weeks post-tumor inoculation, formalin fixed, 
cryopreserved in OCT, or collagenase-digested for flow cytometric analysis. PyMT 
Studies: The growth of spontaneous mammary tumors in PyMT+ (n=10) and Itgam-/-
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;PyMT+ (n=14) animals in the C57Bl6 background was evaluated over the course of 0-
25 weeks. All PyMT+ females exhibited adenomas/ early carcinomas by 16 weeks of 
age and late carcinomas by 25 weeks of age. Total tumor burden at endpoint was 
determined by subtracting the total mammary gland mass in PyMT- animals from the 
total mammary gland mass in PyMT+ animals. 
 
ITGAM I332G knock-in mouse tumor studies: 7.5X105 LLC cells were injected 
subcutaneously (s.c) into the right flank of syngeneic 6- to 8- week old WT or CD11b KI 
mice. Palpable tumors were established at 5-8 days post-tumor inoculation. Tumor 
burden was evaluated 2-3 times a week by caliper measurements and tumor volumes 
were calculated using the equation v = (l2 x w)/2. Tumors and spleens were harvested 
at 4 weeks post-tumor inoculation, weighed, formalin fixed or cryopreserved in OCT for 
histological analysis.   
 
Immunohistochemistry 
Tumor samples were collected and cryopreserved in O.C.T. Sections (5μm) were fixed 
in 100% cold acetone, blocked with 8% normal goat serum for 2 hours, and incubated 
with primary antibodies at 1-5µg/ml for 2 hours at room temperature. Sections were 
washed 3 times with PBS and incubated with fluorescent secondary antibodies. Primary 
antibodies were: F4/80 (BM8, eBioscience), CD4 (H129.19, BD Bioscience), CD8 (53-
6.7, BD Bioscience), CD31 (MEC13.1, BD Bioscience), desmin (RB0914-P1, LabVision, 
Thermo Scientific), and anti-smooth muscle actin (1A4, Sigma-Aldrich). Slides were 
counterstained with 4',6-diamidino-2-phenylindole (DAPI) to identify nuclei. 
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Immunofluorescence images were collected on a Nikon microscope (Eclipse TE2000-U) 
and analyzed using Metamorph image capture and analysis software (Version 6.3r5, 
Molecular Devices). Pixels/field or cell number/field were quantified in five 100x fields 
from 5 biological replicates. For LA1 studies, immunohistochemical staining was 
quantified by counting marker positive cells in 3 different areas analyzed at 40x using a 
light microscope for each tumor tissue (n=4-6). Tissues that were stained with 
fluorochrome conjugated secondary antibodies were counter stained with DAPI and 
analyzed using the Zeiss 700 LSM confocal microscope and Zen software (Carl Zeiss 
Group, Hartford, Connecticut). 
 
Quantification of murine peripheral blood cells  
To quantify myeloid cells in murine peripheral blood, blood was collected from naïve or 
tumor-bearing mice by retro-orbital bleeding into heparin-coated Vacutainer tubes (BD 
Bioscience), incubated in red blood cell lysis buffer. Cells were washed twice in PBS 
and stained for flow cytometric sorting.  
 
Isolation of single cells from murine tumors 
Tumors were isolated, minced in a petri dish on ice and then enzymatically dissociated 
in Hanks Balanced Salt Solution containing 0.5 mg/ml Collagenase IV (Sigma), 0.1 
mg/ml Hyaluronidase V (Sigma) and 0.005 MU/ml DNAse I (Sigma) at 37°C for 5-30 
min. The duration of enzymatic treatment was optimized for greatest yield of live 
CD11b+ cells per tumor type. Cell suspensions were filtered through a 70μm cell 
strainer. Red blood cells were solubilized with red cell lysis buffer (Pharm Lyse, BD 
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Biosciences, San Jose, CA), and the resulting suspension was filtered through a cell 
strainer to produce a single cell suspension. Cells were washed one time with PBS prior 
to use in flow cytometry analysis or sorting.  
 
Flow cytometry staining and analysis 
Single cell suspensions (106 cells in 100 µL total volume) were incubated with Aqua 
Live Dead fixable stain (Life Technologies, Carlsbad, CA), FcR-blocking reagent (BD 
Biosciences, San Jose, CA) and fluorescently labeled antibodies and incubated at 4°C 
for 1h. Primary antibodies were: BV605-F4/80 (clone BM8, Biolegend #123133, 1.25 
µg/ml), Alexa 700-CD45 (clone 30-F11, eBioscience #56-0451, x 0.6 µg/ml), CD11b-
APC (clone M1/70, eBioscience #17-0012, 0.3µg/ml), FITC-Gr1 (clone RB6-8C5, 
eBioscience #11-5931, 3µg/ml), eF780-CD3 (clone 145-2C11, eBioscience #47-0031, 
5µg/ml), PE-Dazzle-CD4 (clone RM4-5, Biolegend #100565, 0.4µg/ml), and BV605-
CD8 (clone 53-6.7, Biolegend #100743, 1.75µg/ml). Multicolor FACS Analysis was 
performed on a BD Canto RUO 11 Color Analyzer. All data analysis was performed 
using the flow cytometry analysis program FloJo (Treestar).   
 
Human macrophage differentiation and culture 
Human leukocytes concentrated by from apheresis were obtained from the San Diego 
Blood Bank. Cells were diluted in phosphate buffered saline (PBS), 0.5% BSA, 2mM 
EDTA, incubated in red cell lysis buffer (155 mM NH4Cl, 10 mM NaHCO3 and 0.1 mM 
EDTA) and centrifuged over Histopaque 1077 to purify mononuclear cells. 
Approximately 109 cells were purified by gradient centrifugation from one apheresis 
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sample. Purified mononuclear cells were cultured in RPMI + 20% serum + 50ng/ml 
Human M-CSF (PeproTech). Non-adherent cells were removed after 2h by washing, 
and adherent cells were cultured for 6 days to differentiate macrophages fully.  
 
Murine macrophage differentiation and culture 
Bone marrow derived cells (BMDC) were aseptically harvested from 6-8 week-old 
female mice by flushing leg bones of euthanized mice with phosphate buffered saline 
(PBS), 0.5% BSA, 2mM EDTA, incubating in red cell lysis buffer (155 mM NH4Cl, 10 
mM NaHCO3 and 0.1 mM EDTA) and centrifuging over Histopaque 1083 to purify the 
mononuclear cells. Approximately 5X107 BMDC were purified by gradient centrifugation 
from the femurs and tibias of a single mouse. Purified mononuclear cells were cultured 
in RPMI + 20% serum + 50ng/ml M-CSF (PeproTech).  
 
Macrophage polarization 
Bone marrow derived macrophages were polarized with either IFNγ (20 ng/ml, 
Peprotech) plus LPS (100 ng/ml, Sigma) or LPS alone for 24h or IL-4 (20 ng/ml, 
Peprotech) for 24-48h. In some cases, macrophages were incubated with inhibitors of 
Stat3 (STAT4 VIII) or cMyc (10058-F4, Selleck). Total RNA was harvested from 
macrophages using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions. Secreted protein was measured in culture supernatants by ELISA assays.  
 
Analysis of gene expression 
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Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen). cDNA was prepared 
using 1µg RNA with the qScript cDNA Synthesis Kit (Quanta Biosciences) or the 
SuperScript III First-Strand Synthesis Kit (Invitrogen). Sybr green-based qPCR was 
performed using primers to murine Gapdh (Mm_Gapdh_1_SG ), Arg1 (Mm_Arg_1_SG 
QT00134288) Tgfb (Mm_Tgfb_1_SG Qiagen QT00145250) , Il10 (Mm_Il10_1_SG 
Qiagen   QT00106169), Il6 (Mm_Il6_1_SG Qiagen QT00098875), Nos2 
(Mm_Nos2_1_SG  Qiagen QT00100275), Il12b (Mm_Il12b_1_SG Qiagen 
QT00153643)Ifng (Mm_Ifng_1_SG Qiagen QT01038821), Il1b (Mm_Il1b_2_SG Qiagen 
QT01048355), Tnfa (Mm_Tnfa_1_SG Qiagen QT00104006), Vegfa (Mm_Vegfa_1_SG 
Qiagen QT00160769), Pdgfb (Mm_Pdgfb_1_SG Qiagen QT00266910) and human 
GAPDH (Hs_GAPDH_1_SG Qiagen QT00079247), ARG1 (Hs_Arginase_1_SG Qiagen 
QT00068446, IL6 (Hs_IL6_1_SG Qiagen QT00083720), NOS2 (Hs_NOS2_1_SG 
Qiagen QT00068740), IL12B (Hs_IL12B_1_SG Qiagen QT00000364), and PDGFB 
(Hs_PDGFB_1_SG Qiagen QT00001260) (Qiagen QuantiTect Primer Assay). mRNA 
levels were normalized to Gapdh or GAPDH (ΔCt = Ct gene of interest – Ct Gapdh) and 
reported as relative mRNA expression (ΔΔCt = 2^-(ΔCt sample – ΔCt control)) or fold 
change.  
 
Immunoblotting 
IL-4 and LPS macrophage cultures were solubilized in RIPA buffer containing protease 
and phosphatase inhibitors. Thirty µg protein was electrophoresed on Biorad precast 
gradient gels and electroblotted onto PVDF membranes. Proteins were detected by 
incubation with 1:1000 dilutions of primary antibodies, washed and incubated with Goat 
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anti-rabbit-HRP antibodies and detected after incubation with a chemiluminescent 
substrate. Primary antibodies directed against NFκBp65 (D14E12, #8242 Cell Signaling 
Technology, 1:1000), pSer536NFκBp65 (93H1, #3033 Cell Signaling Technology, 
1:1000), cMyc (D3N8F, #13987 Cell Signaling Technology, 1:1000) or pSer62 cMyc 
(E1J4K, #13748 Cell Signaling Technology, 1:1000). Anti-actin (#A2103 Sigma-Aldrich, 
1:1000). Uncropped scans of Western blots are included as a supplementary figure in 
the Supplementary Information. 
 
In vivo macrophage adoptive transfer experiments 
F4/80+ cells were isolated from single cell suspensions of 700-800 mg LLC tumors from 
donor WT or Itgam-/- mice by FACS sorting. Primary bone marrow derived 
macrophages from WT or Itgam-/- mice were polarized and harvested into a single cell 
suspension. Alternatively, WT tumor derived macrophages were incubated with LA1 or 
saline. Purified macrophages were admixed 1:1 with LLC tumor cells and 5 x 105 total 
cells were injected subcutaneously into syngeneic host WT or Itgam-/- mice. Tumors 
were excised and weights were determined 14 days after inoculation.  
 
Integrin CD11b ligation experiments  
Differentiated bone marrow derived macrophages were cultured on 5 µg/ml VCAM-1 or 
ICAM-1 (R&D Systems) coated culture plates or maintained in suspension. To inhibit 
integrin CD11b ligation, macrophages were cultured on 5 µg/ml ICAM-1 in the presence 
of 25µg/ml anti-CD11b antibody (M1/70, BD Bioscience) or in suspension culture on 
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BSA coated culture plates. As a control, macrophages were cultured in the presence of 
IgG control antibody. 
 
siRNA mediated knockdown 
Differentiated macrophages were transfected (AMAXA, Mouse Macrophage 
Nucleofection Kit) using 100 nM of siRNA against Itgam (Mm_Itgam_01 or Mm_Itgam-
05) or Il6 (Mm_Il6_01 or Mm_Il6_03) or non-silencing siRNA (Ctrl_AllStars_1) from 
Qiagen. After transfection, cells were cultured for 36-48h in DMEM containing 10% 
serum and 10ng/ml M-CSF (PeproTech). Efficiency of Itgam knockdown of each oligo 
was confirmed by quantitative RT-PCR QuantiTect Primer Assay) and flow cytometry. 
 
MicroRNA and anti-microRNA 
Control miRNA, control anti-miRNA, Pre-miR-Let7a (PM10050) and Anti–miR-Let7a 
(AM10050) for in vitro studies were from Applied Biosystems. MicroRNA was delivered 
using siPORT (Ambion). To evaluate microRNA expression levels, total RNA was 
extracted with Trizol (Invitrogen), and RT-PCR was performed to detect let-7a (Mm_let-
7a-1_2), let 7d (Mm_let-7d_1), or let7f (Mm_let7f-1_1) miScript Primer Assay. Data 
were normalized to the internal control small RNA snoRNA202 (Applied Biosystems). 
For in vivo studies, oligomers were purchased from Sigma: Anti-miR scrambled 
control:5’[mG][mU][mC][mA][mA][mG][mG][mC][mA][mU] 
[mC][mC][mG][mG][mA][mU][mC][mA][mU][mC][mA][mA]-3’ 
Anti-miR-Let7a: 
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5’[mA][mC][mU][mC][mC][mA][mU][mC][mA][mU][mC][mC][mA][mA][mC][mA][mU][mA][
mU][mC][mA][mA]-3’ 
 
Nanoparticle preparation and administration 
The cyclic peptides, cRGDfK and cRADfK, were synthesized by using standard Fmoc 
solid-phase chemistry. Peptides were purified by reverse-phase HPLC, and mass was 
confirmed by mass spectroscopy. Peptides were conjugated to succinimidyl ester-
(PEO)4-maleimide (Pierce). DSPE was reacted with iminothiolane (Sigma–Aldrich) to 
produce a free thiol. The DSPE containing the free thiol group was reacted with the 
cRGDfK-(PEO)4-maleimide or cRADfK-(PEO)4-maleimide to produce peptide-lipid 
conjugates.  
 
Cholesterol/DOPE/DSPC/DSPE-(PEO)4-cRGDfK/DSPE-mPEG2000 (6:6:6:1:1 molar 
ratio) in chloroform was evaporated under argon gas and then hydrated in sterile 300 
mM ammonium phosphate buffer (pH 7.4) at a total lipid concentration of 3.32 mM for 1 
h. Liposomes were vortexed for 2–3 min and sonicated in ULTRAsonik 28X for 2–3 min 
at room temperature to produce multilamellar vesicles (MLVs). MLVs were then 
sonicated with a Ti-probe (Branson 450 sonifier) for 1–2 min to produce small 
unilamellar vesicles (SUVs). Stepwise extrusion was performed with the final step being 
extrusion through a polycarbonate filter with 100-nm pore size (Whatman). Liposomes 
incorporating cyclic peptides  were used to form lipid-RNA complexes43. These 
complexes were formulated with a molar ratio of 4:1 calculated based on the N-[1-(2,3-
dioleoyloxy)]-N,N,N-trimethylammonium propane (DOTAP) content of the liposomes. 
 36
Nucleic acids (anti-miRNAs) and lipids were separately diluted in 100μl RNase-free 
water. The RNA solution was added to the liposomes, mixed gently and the mixture was 
incubated at 25 °C for 5 min before injection into mice. Mice were treated with 5 µg of 
scrambled anti-miRNA or anti–miR-Let7a (Sigma) in RGD-nanoparticles intravenously 
every 3d starting from day 7 until the end of the experiment.   
 
Statistics 
For studies evaluating mutations or drug treatments on tumor size, tumor volumes were 
computed and mice were randomly assigned to groups so that the mean volume +/- 
s.e.m. of each group was identical. A sample size of 10 mice/group provided 80% 
power to detect mean difference of 2.25 standard deviation (SD) between two groups 
(based on a two-sample t-test with 2-sided 5% significance level). Significance testing 
was performed by one-way Anova with Tukey's posthoc testing for multiple pairwise 
testing or by parametric or nonparametric Student’s t test as appropriate. We used a 
two-sample t-test (two groups) and ANOVA (multiple groups) when data were normally 
distributed, a Wilcoxon rank sum test (two groups) when data were not and Fisher’s 
exact test when appropriate. All mouse studies were randomized and blinded; 
assignment of mice to treatment groups, tumor measurement and tumor analysis was 
performed by coding mice with randomly assigned mouse number, with the key 
unknown to operators until experiments were completed. In tumor studies for which 
tumor size was the outcome, animals removed from the study due to health concerns 
were not included in endpoint analyses.  
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source data underlying all figures are provided in as a Source Data file 
(Supplementary Data 1). A reporting summary for this article is available as a 
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Figure 1: CD11b ligation promotes pro-inflammatory macrophage signaling 
 
(a-f) Relative mRNA expression of pro- and anti-inflammatory cytokines in (a) bone 
marrow derived macrophages (BMDM) from WT (white bars) or Itgam-/- (cyan bars) 
mice (n=2-8); (b) tumor associated macrophages (TAM) from WT (white bars) and 
Itgam-/- (cyan bars) mice bearing LLC lung carcinoma tumors (n=2-4); (c) Itgam-/- and 
Itgam or non-silencing siRNA transfected macrophages (n=2-4); inset: cell surface 
expression levels of CD11b in transfected macrophages; (e) WT macrophages in the 
presence of non-specific (IgG) or anti-CD11b antibodies (n=3), (e) murine macrophages 
adherent to ICAM-1, VCAM-1 or BSA coated plates (Susp) (n=3) and (f) human 
macrophages adherent to ICAM-1 or BSA coated plates (Susp) (n=3). (g) 
Immunoblotting of phosphoSer536 and total p65 NFκB RelA in WT and Itgam-/- 
macrophages stimulated with IFNγ + LPS; graph depicts quantification of relative 
pSer536 expression in WT (white bars) and Itgam-/- (blue bars) BMDM. (h-i) LLC tumor 
growth in WT and Itgam-/- mice adoptively transferred with (h) bone marrow derived 
and (i) tumor derived WT or Itgam-/- macrophages. (j) Relative mRNA expression of 
cytokines in whole LLC tumors from WT (white bars) and Itgam-/- (cyan bars) mice 
(n=3). (k) LLC lung (n=17), B16 melanoma (n=9) and autochthonous PyMT mammary 
(n=10-14) tumor weight in WT (black dots) and Itgam-/- (cyan dots) mice. (l) Tumor 
weight and volume of LLC tumors grown in WT (black dots) versus Itgam I332G knockin 
mice (cyan dots) (n=6-7). Error bars indicate sem. "n" indicates biological replicates. p< 
0.05 indicates statistical significance determined by Student's t-test for 1a-g and 1j. and 
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by Anova with Tukey post-hoc testing for 1h-i, 1k-l. Source data are provided in Source 
Data file. 
 
 
 
Figure 2: CD11b suppresses PDGF-BB-dependent neovascularization and tumor 
growth  
 (a) CD31, Desmin, NG2, Smooth muscle actin (SMA) and Dextran immunostaining of 
blood vessels in LLC tumors from WT (white bars) and Itgam-/- (blue bars) mice (n=10). 
(b) Blood vessel density (vessels/field) and number of vessel branch points/field in LLC 
tumors from WT (white bars) and Itgam-/- (blue bars) animals (n=10). (c) Percent 
CD31+/SMA+, CD31+/Desmin+, CD31+/NG2+ vessels in tumors from WT (white bars) 
and Itgam-/- (blue bars)  (n=5). (d) Ratio of extravascular to intravascular FITC-dextran 
in LLC tumors from WT (white bars) and Itgam-/- (blue bars) mice (n=5). (e-f) Pdgfb and 
Vegfa (e) mRNA (n=3) and (f) PDGF-BB protein expression (n=12) in LLC tumors from 
WT (white bars) and Itgam-/- (blue bars) mice (n=3). (g) Left, FITC-Isolectin staining of 
whole mount retinas from newborn WT (white bars) and Itgam-/- (blue bars) mice. Right, 
Percent neovascularization at P1, P4 and P9 retinas in WT (white bars) and Itgam-/- 
(blue bars)  mice (n=5). (h) Desmin (red) and CD31 (green) immunostaining of LLC 
tumors from Imatinib and vehicle-treated WT (white bars) and Itgam-/- (blue bars) mice. 
(i) Tumor weight, number of blood vessels/field and percent Desmin/CD31 vessels per 
field from h (n=10). Bar on micrographs indicates 50 µm. Error bars indicate sem. "n" 
indicates biological replicates. p< 0.05 indicates statistical significance, as determined 
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by Student's t-test for 2b-g and by Anova with Tukey's post-hoc testing for 2i. Source 
data are provided in Source Data file 
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Figure 3: CD11b promotes miR-Let7a mediated immune stimulation  
(a) Relative mRNA expression of pro- and anti-inflammatory factors in WT (white bars) 
and Itgam-/- (blue bars) macrophages incubated with and without the Stat3 inhibitor 
5,15 DPP; inset, Stat3 phosphorylation in WT and Itgam-/- macrophages (n=2-3). (b) 
Relative mRNA expression of pro- and anti-inflammatory factors in IL6-stimulated 
human (white bars) and murine (cyan bars) bone marrow-derived macrophages and 
murine total bone marrow derived myeloid cells (blue bars)  (n=3); p < 0.05 with these 
exceptions: mBMM (Ifng, Il12b); mCD11b+ (Arg1, Pdgfb, Il12b and Il1b); hBMM (Arg1, 
Ifng, Il1b). (c) Relative Il6 and Pdgfb mRNA expression in WT and Itgam-/- cells 
transduced with non-silencing (white bars or Il6 (blue bars) siRNA (n=3). (d) Relative 
Let7a expression in murine macrophages transduced with non-silencing (white bars) or 
Itgam (blue bars) siRNAs, macrophages incubated with control IgG (white bars) or 
neutralizing anti-CD11b (blue bars) antibodies, and WT (white bars) or Itgam-/- (blue 
bars) macrophages (n=3). (e) Time course of Let7a (left) and Il6 (right) expression in 
WT murine CD11b+ cells seeded on ICAM-1 (blue solid line) or maintained in 
suspension (black dotted line) (n=3). (f) Relative expression of miRNA Let7a and Il6 in 
human macrophages adherent to ICAM-1 (blue) or maintained in suspension (white) 
(n=3). (g) Relative mRNA expression of inflammatory factors in WT and Itgam-/- BMM 
transduced with control (white bars), pre-miRNA Let7a (cyan bars) or anti-miRNA Let7a 
(blue bars) (n=3). (h) Relative Pdgfb and Vegfa expression in WT BMM transduced with 
control (white bars) or anti-miRNA Let7a (blue bars) (n=3). (i) Time course of c-Myc 
expression in IL-4 or IFNγ + LPS stimulated WT (black lines) or Itgam-/- (blue lines) 
macrophages (n=3). (j) Time course of c-Myc expression and pSer62myc 
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phosphorylation in WT and Itgam-/- macrophages. (k) Relative mRNA expression of 
miRNAs Let7a (white bars), Let7d (blue bars) and Let7f (cyan bars) in basal, IL-4, or IL-
4 + c-myc inhibitor treated WT and Itgam-/- macrophages (n=3). (l) Relative mRNA 
expression of Il6, Arg1, and Pdgfb in IL-4 stimulated WT (white bars) and Itgam-/- (blue 
bars) macrophages treated with (blue bars) or without (white bars) c-Myc inhibitor 
10058-F4. Error bars indicate sem. "n" indicates biological replicates. *p (< 0.05) 
indicates statistical significance determined by Student's t-test for 3a, 3d-f, and Anova 
with Tukey's post-hoc testing for 3b, g, k. Source data are provided as a Source Data 
file. 
 
Figure 4: Macrophage microRNA let-7a is required for tumor growth suppression. 
(a-b) Endothelial cells and vascular smooth muscle cells attached to microcarrier beads 
were cultured in fibrin gels containing WT or Itgam-/- BMMs transduced with control 
miRNA, pre-miRNA Let7a, anti-miRNA Let7a or Pdgf-bb siRNA. (a) images (b) 
histograms of CD31+ positive vessel length (mm) (n=10). (c) CD31 (green) and SMA 
(red) immunostaining of sections from in vivo cultured bFGF-saturated Matrigel plugs 
containing BMM transduced with control miR (black bars) or anti-miR Let7a (blue bars); 
quantification of the percentage of SMA+ vessels per matrigel plug (n=25). (d) 
Schematic and graph of targeted delivery of anti-miR Let7a in animals with LLC tumors; 
tumor volumes from control anti-miRNA (black line) or anti-miRNA Let-7a (cyan line) 
treated animals (n=10). (e) Let7a expression in cell populations sorted from peripheral 
blood cell and tumors from control (black bars) and anti-miRNA Let7-treated (cyan bars) 
animals from d (n=3). (f) Relative mRNA expression of inflammatory factors in sorted 
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macrophages from d (n=3). (g) Representative images of CD31/Desmin co-localization 
and FITC-Dextran localization in treated tumors from d. (h) Quantification of the 
percentage of CD31/Desmin co-localization (n=30) and of FITC-dextran leakage into 
tissues (n=25). (i) CD4+ and CD8+ cells/field in tumors from control anti-miR (black bars                      
) or anti-miR let-7a (blue bars) transduced animals (n=25) scale bars, 40 µm. (j) 
Schematic representation of chemotherapeutic treatment in combination with targeted 
delivery of anti-miR-let7a. (k) Volumes and endpoint weights of LLC tumors in animals 
transduced with control anti-miR (black), anti-miR let-7a (blue), control anti-miR 
/Gemcitabine (green), and anti-miR let7a/Gemcitabine (red) (n=10). Bar on micrographs 
indicates 50µm. Error bars indicate sem. "n" indicates biological replicates. *p (< 0.05) 
indicates statistical significance by Student's t-test for 4c-i and by Anova with Tukey's 
post-hoc testing for 4j  Source data are provided as a Source Data file. 
 
 
Figure 5. Integrin CD11b agonism suppresses tumor growth and promotes 
survival in mouse models of cancer 
(a) Structure of LA1. (b) Adhesion of macrophages in the absence or presence of 
Ca2+Mg2+ (white bars) Mn2+ (black bars), LA1 (cyan bars) or LA1+ neutralizing anti-
CD11b (grey bars) (n=3). (c) Relative mRNA expression of Let7a, Il16 or Pdgfb in 
control (black bars) and LA1 (cyan bars) -treated macrophages (n=3). (d) Tumor 
weights 16 days after implantation of LLC cells mixed 1:1 with control-treated (dots), 
DMSO-treated (triangles) or LA1-treated (diamonds) tumor-derived macrophages (n=8). 
(e) Tumor growth curves as represented by volumes from d: control (black line), vehicle 
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(grey line) and LA1 (red line) (n=8). (f) Effect of LA1 on in vitro proliferation of LLC cells 
and macrophages (n=4). (g) Tumor volumes of orthotopic CL66 breast tumors treated 
with vehicle (black line), Taxol (grey line), LA1 (dark blue line) or LA1 + Taxol (cyan line) 
(n=10-15). (h) Tumor volumes of orthotopic CL66 tumors treated with vehicle (black 
line), irradiation (grey line) (IR, 20 Gy), LA1 (dark blue line) (2 mg/kg), or LA1+IR (cyan 
line) (n=9). (i) Tumor volumes of orthotopic human MDA-MB-231 mammary xenografts 
treated with vehicle (control, black line), Taxol (grey line), or LA1 (blue line) (n=7). (j-k) 
Mean LLC subcutaneous tumor volumes of (j) WT (black line) and (k) Itgam-/- (cyan 
line) mice treated with and without LA1 (n=6). (l) Images and quantification of 
SMA/CD31 expression in blood vessels of control (black bars) and LA1 treated (cyan 
bars) animals from g, i, and j. Bar on micrographs indicates 50µm. (m) Schematic 
depicting role of CD11b activation in the control of immune stimulation. Error bars 
indicate sem. "n" indicates biological replicates. *p (<0.5) indicates statistical 
significance by Student's t-test 5c, 5f; Anova with Tukey post-hoc testing for 5d-e; 
unpaired t-test 5g, 5i; Mann-Whitney t-test 5b, 5j-l; Wilcox test 5h. Source data are 
provided as a Source Data file. 
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